Related Experiment Video
Updated: Nov 16, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Cardiac Complications in COVID-19: A Systematic Review and Meta-analysis
Mehrdad Sahranavard1, Arash Akhavan Rezayat2,3, Mohammad Zamiri Bidary3
1Student Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Insights
COVID-19 frequently impacts the heart, with significant rates of myocardial injury and heart failure. Elevated cardiac troponin I (cTnI) levels were notably higher in non-surviving patients, indicating severe cardiac involvement.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- The COVID-19 pandemic has revealed multi-organ involvement, including the cardiovascular system.
- Understanding cardiac complications is crucial for managing COVID-19 patients.
- Systematic review and meta-analysis are essential for synthesizing evidence on COVID-19's cardiac effects.
Purpose of the Study:
- To systematically review and calculate the pooled incidences of cardiac complications in COVID-19 patients.
- To compare cardiac troponin I (cTnI) levels between surviving and non-surviving COVID-19 patients.
Main Methods:
- A systematic literature search was performed for studies published between December 2019 and April 2020.
- Data on cardiovascular complications and cardiac biomarkers (cTnI, CK, CK-MB) were extracted from hospitalized, PCR-confirmed COVID-19 cases.
- Pooled incidences were calculated, and cTnI levels were compared between survivors and non-survivors.
Main Results:
- The pooled incidence of arrhythmia was 10.11%, myocardial injury was 17.85%, and heart failure was 22.34%.
- Pooled incidence rates for elevated cTnI, CK-MB, and CK were 15.16%, 10.92%, and 12.99%, respectively.
- Non-survivors exhibited significantly higher pooled cTnI levels compared to survivors (mean difference = 31.818, P < 0.001).
Conclusions:
- COVID-19 significantly affects the cardiovascular system, with the myocardium being particularly vulnerable.
- Elevated cTnI levels are a strong indicator of disease severity and mortality in COVID-19 patients.
- These findings highlight the importance of cardiac monitoring in COVID-19 management.
Background:
The newly emerged coronavirus disease 2019 (COVID-19) seems to involve different organs, including the cardiovascular system. We systematically reviewed COVID-19 cardiac complications and calculated their pooled incidences. Secondarily, we compared the cardiac troponin I (cTnI) level between the surviving and expired patients.
Methods:
A systematic search was conducted for manuscripts published from December 1, 2019 to April 16, 2020. Cardiovascular complications, along with the levels of cTnI, creatine kinase (CK), and creatine kinase MB (CK-MB) in hospitalized PCR-confirmed COVID-19 patients were extracted. The pooled incidences of the extracted data were calculated, and the unadjusted cTnI level was compared between the surviving and expired patients.
Results:
Out of 1094 obtained records, 22 studies on a total of 4,157 patients were included. The pooled incidence rate of arrhythmia was 10.11%. Furthermore, myocardial injury had a pooled incidence of 17.85%, and finally, the pooled incidence for heart failure was 22.34%. The pooled incidence rates of cTnI, CK-MB, and CK elevations were also reported at 15.16%, 10.92%, and 12.99%, respectively. Moreover, the pooled level of unadjusted cTnI was significantly higher in expired cases compared with the surviving (mean difference = 31.818, 95% CI = 17.923-45.713, P value <0.001).
Conclusion:
COVID-19 can affect different parts of the heart; however, the myocardium is more involved.
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Introduction Cardiac Emergencies
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

